Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates

Song, Aihua; Myojo, Kensuke; Laudenslager, John; Harada, Daisuke; Miura, Tsuyoshi; Suzuki, Kazuo; Kuni-Kamochi, Reiko; Soloff, Rachel; Ohgami, Kinya; Kanda, Yutaka

doi:10.1016/j.antiviral.2014.08.016

Cited by 24 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Passive immunotherapy with Z3G1 significantly protected mice from influenza A infection via ADCC. 123,124 These results indicate that M2 may also induce protection through an ADCC-dependent mechanism. …”

Section: Universal Antibody-dependent Cell-mediated Cytotoxicitymentioning

confidence: 90%

Progress on adenovirus-vectored universal influenza vaccines

Xiang

Guan

Zhou

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Influenza virus (IFV) infection causes serious health problems and heavy financial burdens each year worldwide. The classical inactivated influenza virus vaccine (IIVV) and live attenuated influenza vaccine (LAIV) must be updated regularly to match the new strains that evolve due to antigenic drift and antigenic shift. However, with the discovery of broadly neutralizing antibodies that recognize conserved antigens, and the CD8(+) T cell responses targeting viral internal proteins nucleoprotein (NP), matrix protein 1 (M1) and polymerase basic 1 (PB1), it is possible to develop a universal influenza vaccine based on the conserved hemagglutinin (HA) stem, NP, and matrix proteins. Recombinant adenovirus (rAd) is an ideal influenza vaccine vector because it has an ideal stability and safety profile, induces balanced humoral and cell-mediated immune responses due to activation of innate immunity, provides 'self-adjuvanting' activity, can mimic natural IFV infection, and confers seamless protection against mucosal pathogens. Moreover, this vector can be developed as a low-cost, rapid-response vaccine that can be quickly manufactured. Therefore, an adenovirus vector encoding conserved influenza antigens holds promise in the development of a universal influenza vaccine. This review will summarize the progress in adenovirus-vectored universal flu vaccines and discuss future novel approaches.

show abstract

Section: Universal Antibody-dependent Cell-mediated Cytotoxicitymentioning

confidence: 90%

Progress on adenovirus-vectored universal influenza vaccines

Xiang

Guan

Zhou

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Furthermore, Z3G1 offered protection in mice infected with different strains of influenza virus, including amantadine-and oseltamivir-resistant strains [20]. As well, Z3G1 reduced lung pathology in monkeys infected with a 2009 pH1N1 strain [20]. Another humanized monoclonal antibody with neutralizing activity against the pH1N1 influenza virus was expressed in a m ammalian cell line [21].…”

Section: Therapeutic Antibodiesmentioning

confidence: 97%

“…The treatment with Z3G1 can be administered at late as 3 days postinfection, and it still offered significant protection of mice against the lethal virus challenge. Furthermore, Z3G1 offered protection in mice infected with different strains of influenza virus, including amantadine-and oseltamivir-resistant strains [20]. As well, Z3G1 reduced lung pathology in monkeys infected with a 2009 pH1N1 strain [20].…”

Section: Therapeutic Antibodiesmentioning

confidence: 98%

“…For example, monoclonal antibodies can be generated from transgenic mice engineered to produce fully humanized antibodies following immunization with a consensus-sequence viral antigen. In one such study, several humanized monoclonal antibodies were generated following immunization of transgenic mice using a consensus-sequence of the influenza M2 protein [19], among which is one monoclonal antibody (Z3G1) with high affinity binding to the majority of M2 protein from natural viral isolates, including the highly pathogenic avian strains [20]. Passive immunotherapy with this monoclonal antibody protected mice from a lethal virus challenge and resulted in significant reduction in viral replication, when the antibody was administered to the mice prophylactically or therapeutically.…”

Section: Therapeutic Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Experimental Antiviral Drugs Against Pandemic Influenza

Wong¹

2015

Future Virol.

View full text Add to dashboard Cite

The aim of this review is to selectively identify some representative experimental antiviral drugs which are promising in preclinical and clinical studies, but yet to be fully licensed, and discuss how they have a potential role in complementing our existing arsenal of antiviral drugs to combat pandemic influenza. This review will focus on discussing their mechanisms of actions, current state of development, safety, efficacy from preclinical and/or clinical studies. These experimental drugs can be classified into virus or host specific, depending on the individual drug's targeting action. This article will highlight novel anti-inflammatory drugs which can be used to mitigate cytokine storm caused by pandemic influenza viruses as a treatment option or strategy.

show abstract

“…In a recent study of antibody therapy, Song et al generated mab Z3G1 against the M2 matrix protein, which cross-reacted against M2 of a wide range of influenza A viruses (Song et al, 2014). When the investigators challenged cynomolgus macaques with an isolate of the 2009 pandemic H1N1 virus and gave them IV Z3G1 the day before or the day after infection, they observed less weight loss, a maintenance in blood oxygen saturation and less lung damage at necropsy, compared to controls; however, treatment did not prevent fever or reduce virus shedding.…”

Section: Experimental Infections Of Nhps With Human Influenza VImentioning

confidence: 99%

The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893–2014

2015

View full text Add to dashboard Cite

Attempts to reproduce the features of human influenza in laboratory animals date from the early 1890s, when Richard Pfeiffer inoculated apes with bacteria recovered from influenza patients and produced a mild respiratory illness. Numerous studies employing nonhuman primates (NHPs) were performed during the 1918 pandemic and the following decade. Most used bacterial preparations to infect animals, but some sought a filterable agent for the disease. Since the viral etiology of influenza was established in the early 1930s, studies in NHPs have been supplemented by a much larger number of experiments in mice, ferrets and human volunteers. However, the emergence of a novel swine-origin H1N1 influenza virus in 1976 and the highly pathogenic H5N1 avian influenza virus in 1997 stimulated an increase in NHP research, because these agents are difficult to study in naturally infected patients and cannot be administered to human volunteers. In this paper, we review the published literature on the use of NHPs in influenza research from 1893 through the end of 2014. The first section summarizes observational studies of naturally occurring influenza-like syndromes in wild and captive primates, including serologic investigations. The second provides a chronological account of experimental infections of NHPs, beginning with Pfeiffer’s study and covering all published research on seasonal and pandemic influenza viruses, including vaccine and antiviral drug testing. The third section reviews experimental infections of NHPs with avian influenza viruses that have caused disease in humans since 1997. The paper concludes with suggestions for further studies to more clearly define and optimize the role of NHPs as experimental animals for influenza research.

show abstract

Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates

Cited by 24 publications

References 44 publications

Progress on adenovirus-vectored universal influenza vaccines

Progress on adenovirus-vectored universal influenza vaccines

Experimental Antiviral Drugs Against Pandemic Influenza

The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893–2014

Contact Info

Product

Resources

About